CJC-1295 for Health & Longevity

Evidence Review created on 04/21/2026 using AI4L / Opus 4.7

Also known as: DAC:GRF, CJC-1295 with DAC, CJC-1295 DAC, CJC-1295 no DAC, Modified GRF (1-29), tetrasubstituted GRF (1-29)

Motivation

CJC-1295 is a synthetic, long-acting peptide designed to prompt the pituitary gland to release more of the body’s own growth hormone. It attaches to a blood protein called albumin, allowing it to linger in circulation for several days and produce sustained growth-hormone signaling from a single weekly injection.

Originally developed by ConjuChem in the early 2000s for AIDS-related fat redistribution and growth-hormone deficiency, the peptide never completed late-stage trials and was never approved for any clinical indication. It migrated instead into anti-aging, bodybuilding, and longevity-clinic circles, where it is frequently combined with other peptides and marketed for body composition, recovery, and sleep. Regulatory status has shifted repeatedly between restricted and unrestricted status without formal approval.

This review examines what is actually known about CJC-1295 — the small human trial base, the uncertainty around long-term safety, the reasons it remains unapproved, and the gap between laboratory findings and the claims made in commercial peptide marketing.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists high-level overview content on CJC-1295 from expert commentators, podcasts, and qualifying articles.

• AMA #83: Peptides — evaluating the science, safety, and hype in a rapidly growing field - Attia

  Peter Attia dedicates a case-study segment of this AMA to CJC-1295, laying out its GH (growth hormone)-stimulating mechanism, the limited human evidence, dosing uncertainty, and his risk-reward framework for unapproved peptides.

• Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity - Huberman

  A long-form conversation between Andrew Huberman and physician Craig Koniver that covers CJC-1295 specifically in the context of GH secretagogue (drugs that prompt the body to release its own growth hormone) stacks, clinical use patterns, and the 2024 FDA reclassification.

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults - Teichman et al., 2006

  The foundational Phase I human pharmacokinetic and pharmacodynamic paper — the single most cited source defining what CJC-1295 does in healthy adults and the basis for nearly every subsequent dosing claim.

• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions - Van Hout & Hearne, 2016

  A qualitative review of online forum discourse around non-medical CJC-1295 use, useful for understanding how the peptide is actually used outside clinical settings and the folk-pharmacology risks that result.

Note: Only four high-quality items were located. No dedicated, intervention-specific coverage of CJC-1295 was found on foundmyfitness.com (Rhonda Patrick), chriskresser.com, or lifeextension.com at the time of review, and Grokipedia content is listed separately in its dedicated section below.

Grokipedia

• CJC-1295

  The Grokipedia article covers development history, the ConjuChem origin, mechanism of action, human and preclinical trial findings, FDA status, and WADA (World Anti-Doping Agency) prohibition — making it a useful single-source reference for the compound.

Examine

No article for CJC-1295 exists on Examine.com. Examine.com does not typically cover prescription, investigational, or injectable peptide drugs — its coverage focuses on dietary supplements and foods.

ConsumerLab

No article for CJC-1295 exists on ConsumerLab.com. ConsumerLab does not typically cover prescription or investigational peptides — its product testing focuses on dietary supplements, vitamins, and herbal products.

Systematic Reviews

No systematic reviews or meta-analyses for CJC-1295 were found on PubMed as of 04/21/2026.

Mechanism of Action

CJC-1295 is a synthetic, tetrasubstituted analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH, the hypothalamic peptide that signals the pituitary to secrete growth hormone). Four amino acid substitutions (at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase-IV (DPP-IV, the enzyme that rapidly degrades native GHRH). In the “DAC” form, a maleimidopropionamide group on a C-terminal lysine forms a covalent bond with cysteine-34 of circulating albumin (the most abundant plasma protein), producing an albumin-bound depot with a plasma half-life of approximately 5.8–8.1 days in humans (Teichman 2006, Jetté 2005).

Once bound to the GHRH receptor on pituitary somatotroph cells, CJC-1295 triggers cyclic AMP–mediated synthesis and pulsatile release of growth hormone (GH). Continuous GHRH-receptor stimulation from the long-acting DAC form markedly elevates basal (trough) GH levels while preserving natural pulse frequency (Ionescu 2006). GH in turn stimulates hepatic and peripheral IGF-1 (insulin-like growth factor 1) production, which mediates most downstream anabolic effects on muscle, bone, and connective tissue.

A competing mechanistic perspective argues that continuous elevation of trough GH is non-physiological — endogenous GH secretion is sharply pulsatile — and that sustained IGF-1 elevation may uncouple tissue-level growth signaling from normal feedback regulation, potentially amplifying proliferative signaling over time. This concern underlies long-term safety uncertainty.

Key pharmacological properties:

• Half-life: ~5.8–8.1 days (DAC form); ~30 minutes (no-DAC/modified GRF 1-29 form)
• Selectivity: Selective GHRH receptor agonist; does not act on the ghrelin/GHS-R1a (growth hormone secretagogue receptor type 1a) receptor (unlike ipamorelin or GHRP-6)
• Tissue distribution: Albumin-bound, largely confined to plasma and well-perfused tissues
• Metabolism: Proteolytic degradation in plasma and tissues; no significant CYP450 (cytochrome P450, the liver’s main drug-metabolizing enzyme family) involvement

Historical Context & Evolution

CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies (Montreal, Canada) using its proprietary “Drug Affinity Complex” albumin-tethering platform. The original intended use was a long-acting GHRH replacement for pediatric and adult growth hormone deficiency and for HIV (human immunodeficiency virus)-associated lipodystrophy (abnormal body-fat redistribution) — conditions where the short half-life of native GHRH and of sermorelin (an earlier GHRH(1-29) analog that was FDA-approved in 1997 and withdrawn in 2008 for commercial reasons) limited clinical utility.

A Phase II trial in HIV-associated visceral obesity (NCT00267527) was initiated in 2005 but was terminated. ConjuChem’s publicly traded lead program shifted and no Phase III program was pursued. The compound was never submitted for FDA approval for any indication.

The peptide came to be considered for general health optimization through a parallel, non-pharmaceutical route. Early-2010s bodybuilding forums and anti-aging clinics — drawing on the published Phase I data and on Frohman’s mechanistic papers — began using research-grade CJC-1295 off-label, typically combined with ipamorelin. The rationale was that a GHRH analog combined with a ghrelin-receptor agonist could produce synergistic, relatively clean GH pulses without the side effects of exogenous recombinant GH.

Regulatory history is active and shifting. The World Anti-Doping Agency (WADA) prohibits CJC-1295 under Class S2 (peptide hormones). In late 2023 the FDA placed CJC-1295 into Category 2 of its interim compounding policy (substances presenting significant safety risks), which restricted 503A compounding-pharmacy access. In September 2024 the FDA removed CJC-1295 and several other peptides from Category 2 after the original bulk-drug-substance nominators withdrew — not an approval, but a return to an unresolved regulatory state. A PCAC (Pharmacy Compounding Advisory Committee) review of several peptides including CJC-1295 is scheduled for subsequent evaluation rounds. The evolution is not “settled” — what changed is the regulatory posture, not the underlying human evidence base, which remains small.

Expected Benefits

A dedicated search of the published human trial base, expert commentary, and clinical practice sources was performed to assemble this list. The evidence base is dominated by short-duration Phase I/II studies in healthy adults or specific patient populations; long-term outcome trials in healthy longevity-seeking adults do not exist.

Medium 🟩 🟩

Sustained elevation of GH and IGF-1

The core pharmacodynamic effect is robustly documented: subcutaneous CJC-1295 produces dose-dependent 2- to 10-fold increases in plasma GH for ≥6 days and 1.5- to 3-fold elevations in IGF-1 for 9–11 days after a single dose, with IGF-1 remaining above baseline for up to 28 days after multiple weekly doses (Teichman 2006). Pulsatility is preserved while basal GH rises (Ionescu 2006). This benefit is a surrogate endpoint — it is the biochemical lever through which all other claimed benefits are hypothesized to operate, not an outcome in itself.

Magnitude: GH AUC (area under the curve, total exposure over time) increased 7.5-fold at trough; IGF-1 increased 45–60% over 7 days at 60 µg/kg.

Low 🟩

Improvement in body composition (lean mass, fat mass)

Increased GH/IGF-1 axis activity is associated with modest increases in lean body mass and modest reductions in fat mass in GH-deficient adults and in small healthy-adult studies of related GH secretagogues. Direct body-composition endpoints for CJC-1295 specifically in healthy adults come from small, short-duration trials and from clinical-practice observational data. The FDA-approved GHRH analog tesamorelin provides a proxy signal (15–18% reduction in visceral adipose tissue over 26 weeks in HIV-lipodystrophy patients), but the two compounds differ in pharmacokinetics and population.

Magnitude: Not quantified in available studies.

Improved sleep depth (slow-wave sleep)

GH secretion is physiologically tied to slow-wave (deep) sleep, and GHRH analogs have been shown in small studies to increase slow-wave sleep duration. Clinical-practice reports with CJC-1295/ipamorelin consistently describe improved subjective sleep quality, particularly in users who dose in the evening. Mechanistic plausibility is strong but controlled sleep-architecture data for CJC-1295 specifically are absent.

Magnitude: Not quantified in available studies.

Enhanced recovery from exercise and soft-tissue injury

IGF-1 promotes myocyte proliferation, collagen synthesis, and connective-tissue repair. Patient-reported outcomes in longevity-clinic cohorts emphasize recovery and injury-healing benefits, and the mechanism is well-established from broader GH/IGF-1 literature. Direct controlled trials of CJC-1295 for recovery endpoints do not exist.

Magnitude: Not quantified in available studies.

Speculative 🟨

Skin thickness and collagen density

Sustained IGF-1 elevation stimulates dermal fibroblast activity and collagen I/III synthesis in vitro and in animal models. Users and clinicians report improved skin texture and thickness over months, but no controlled CJC-1295 trials have measured dermal endpoints. This claim is based on mechanism plus anecdote.

Cognitive and mood effects

GH and IGF-1 receptors are expressed in the hippocampus and cortex, and GH replacement in deficient adults improves quality-of-life scores. Whether sustained IGF-1 elevation from a GHRH analog produces cognitive benefits in non-deficient adults is unknown. No CJC-1295 trial has measured cognitive endpoints.

Longevity / healthspan extension ⚠️ Conflicted

This is the framing under which CJC-1295 is most heavily marketed in longevity clinics. There is no direct human evidence that CJC-1295 extends healthspan or lifespan. The mechanistic argument — that maintaining youthful GH/IGF-1 levels counters age-related somatopause (the gradual decline in growth-hormone output that occurs with normal aging) — is opposed by a substantial body of evidence (from Laron syndrome cohorts, calorie-restriction studies, and mouse knockout models) suggesting that reduced, not elevated, GH/IGF-1 signaling is associated with longer lifespan. The evidence cuts both ways and the net effect on longevity in non-deficient adults is genuinely unknown.

Benefit-Modifying Factors

• Genetic polymorphisms: The GHR (growth hormone receptor) exon-3 deletion polymorphism (a common variant that removes a short segment of the receptor gene, resulting in a more responsive receptor) modifies downstream GH signaling and is associated with larger body-composition and IGF-1 responses to GH-axis therapy in multiple cohorts. IGF-1 promoter polymorphisms influence baseline IGF-1 and may shift the achievable response window. No well-validated CJC-1295-specific pharmacogenetic markers exist.

• Baseline IGF-1 level: Adults with baseline IGF-1 in the lower tertile for their age show larger absolute and relative IGF-1 response. Those already near the upper reference range have a smaller window for benefit and a higher likelihood of pushing IGF-1 into a supraphysiological zone.

• Age and somatopause stage: Age-related decline in endogenous GHRH secretion and pituitary somatotroph responsiveness begins in the third decade. Older adults (50+) typically show larger percent increases in GH/IGF-1 but also have reduced organ reserve for handling supraphysiological IGF-1 exposure.

• Pituitary integrity: Any structural pituitary disease (adenoma, prior radiation, traumatic injury) reduces or eliminates response, as CJC-1295 requires intact somatotroph function.

• Sex-based differences: Women have higher basal GH pulse amplitude driven by estrogen effects on hepatic IGF-1 production and may require different dosing. Van Hout & Hearne (2016) noted female users describing dosing uncertainty specifically because most published trial data are in men.

• Sleep quality and timing: GH pulses are tightly coupled to slow-wave sleep. Chronic sleep restriction blunts the GH response to any secretagogue. Dosing timing (evening vs. morning) meaningfully affects the pulse pattern.

• Body composition and adiposity: Visceral adiposity blunts endogenous GH secretion; obese individuals may show reduced (not enhanced) response to GHRH analogs.

• Concurrent anabolic signaling (exercise, nutrition): Resistance training and adequate protein intake amplify IGF-1–mediated anabolic effects; sedentary users experience mainly biochemical change with less tissue-level translation.

Potential Risks & Side Effects

A dedicated search of prescribing-information-style sources, FDA adverse event communications, the published trial base, and post-market/folk-use reports was performed. The absence of long-term controlled safety data is the single most important risk-profile finding.

High 🟥 🟥 🟥

Unregulated supply and contamination risk

This is the dominant real-world risk. CJC-1295 is not an FDA-approved drug, and most non-clinic supply is labeled “research use only,” produced in facilities with no pharmaceutical-grade quality control. Published analyses have found preparations with misidentified compounds, variable potency, bacterial endotoxin contamination, and heavy metal residues. This risk is independent of the pharmacology of the compound itself (Henninge 2010; Van Hout 2016).

Magnitude: Contamination or misidentification found in a significant fraction of non-pharmaceutical-grade samples tested.

Unknown long-term safety

No human trial has evaluated CJC-1295 beyond ~13 weeks of continuous use. Multi-year safety data do not exist. Whether sustained supraphysiological IGF-1 elevation over years alters cancer risk, cardiac structure, or metabolic function in originally healthy adults is unknown. Extrapolation from acromegaly (a disease of sustained growth-hormone overproduction where chronic pathological GH/IGF-1 elevation increases cancer, cardiovascular, and mortality risk) is mechanistically relevant but not clinically proven for secretagogue-driven elevations within the reference range.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Fluid retention and peripheral edema

GH/IGF-1 elevation promotes sodium retention and extracellular fluid expansion. Peripheral edema, transient weight gain of 1–3 kg, and puffiness are the most commonly reported side effects in both clinical trials and practice cohorts, typically appearing in the first 2–4 weeks and often dose-limiting. Reported in roughly 10–15% of users at commonly used doses.

Magnitude: ~11% incidence in longer-term observational cohorts; 1–3 kg transient weight gain.

Carpal tunnel and nerve compression symptoms

Related to the fluid-retention mechanism, GH-mediated soft-tissue swelling can compress the median nerve at the wrist, producing numbness, tingling, and pain. This is a well-documented effect of recombinant GH and is reported with CJC-1295 at higher doses.

Magnitude: Reported in ~4% of long-term peptide-clinic cohorts; typically reversible with dose reduction.

Impaired glucose tolerance and insulin resistance

GH directly antagonizes insulin at hepatic and peripheral tissues. Sustained elevation can raise fasting glucose, HbA1c (glycated hemoglobin, a three-month average of blood sugar), and fasting insulin, particularly in users with pre-existing insulin resistance, obesity, or prediabetes. This risk is higher with the long-acting DAC form because trough GH never normalizes.

Magnitude: Not quantified in available studies.

Injection-site reactions

Subcutaneous peptide injection commonly produces local erythema, itching, induration, or transient nodules. Typically mild and self-limited but can be persistent with poor injection technique or low-purity product.

Magnitude: Reported in ~10–20% of users.

Low 🟥

Transient vasodilatory flushing, headache, and tachycardia

Early post-injection flushing, sensation of warmth, and mild tachycardia have been reported and are the likely basis for some of the adverse-event signals that led to FDA Category 2 placement in 2023. Typically minor and self-limited.

Magnitude: Reported in 5–10% of users; usually resolves within minutes to hours.

Suppression of endogenous GHRH / somatotroph axis

Chronic exogenous stimulation theoretically risks downregulation of hypothalamic GHRH secretion or somatotroph desensitization. Short-term studies do not show sustained suppression after withdrawal, but long-term data are absent.

Magnitude: Not quantified in available studies.

Speculative 🟨

Elevated cancer risk from sustained IGF-1 elevation ⚠️ Conflicted

Population epidemiology associates the upper quartile of IGF-1 with modestly elevated risk of prostate, breast, and colorectal cancer. Mendelian randomization studies support causality for some cancer types. Against this, short-term GH/IGF-1 therapy in deficient adults has not shown increased cancer incidence in clinical trials. Whether CJC-1295–driven IGF-1 elevation over months to years in otherwise healthy adults meaningfully alters cancer risk is unresolved. Individuals with active or historical malignancy should avoid growth-hormone secretagogues.

Cardiac hypertrophy and remodeling

Chronic pathological GH excess (acromegaly) causes biventricular hypertrophy and diastolic dysfunction. Whether sub-acromegalic, secretagogue-driven elevation produces any cardiac structural change over years is unstudied.

Immunogenicity

As a synthetic peptide, CJC-1295 has some theoretical immunogenic potential, particularly given its covalent albumin conjugation. Anti-drug antibodies have been reported in at least one FDA communication. Clinical significance is unclear.

Risk-Modifying Factors

• Genetic polymorphisms: Variants associated with higher baseline IGF-1 (IGF-1 promoter CA-repeat polymorphisms) or with stronger GH signaling (GHR exon-3 deletion) may predispose to supraphysiological IGF-1 exposure and its associated theoretical risks (cancer signaling, cardiac remodeling). Polymorphisms in insulin-signaling genes may also modify the glucose-elevation risk.

• Pre-existing diabetes or prediabetes: Meaningfully raises the probability of clinically relevant glucose elevation from sustained GH exposure.

• Personal or family history of cancer: A hormone-sensitive cancer history (prostate, breast, colorectal) shifts the unknown-long-term-risk profile unfavorably.

• Age-related considerations: Older adults (65+) may have greater sensitivity to fluid retention, blood-pressure elevation, and cardiac-structural effects, and lower reserve for managing supraphysiological IGF-1.

• Baseline IGF-1 already at or above age-adjusted reference range: Additional elevation moves into supraphysiological territory with less favorable risk-benefit.

• Pituitary or hypothalamic disease: Structural disease may produce unpredictable response magnitude.

• Source/supplier quality: Non-pharmaceutical-grade supply dominates the market; supplier quality is arguably the single largest determinant of real-world safety.

• Sex-based differences: Women have less trial data; dose extrapolation from male-dominant studies introduces uncertainty.

• Concurrent use of other GH-axis agents: Stacking with ipamorelin, GHRP-2/6 (growth hormone-releasing peptides 2 and 6, synthetic ghrelin-receptor agonists), MK-677 (ibutamoren, an orally active ghrelin-receptor agonist), or recombinant GH compounds risk multiplicatively.

Key Interactions & Contraindications

• Recombinant growth hormone (somatropin): Additive — concurrent use produces supraphysiological GH/IGF-1 with sharply increased side-effect burden. Avoid.

• Other GH secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677/ibutamoren): Commonly co-administered in practice; additive effects on GH/IGF-1 and fluid retention; severity ranges from caution to absolute contraindication depending on dosing.

• Insulin and oral antidiabetic drugs (metformin, sulfonylureas (a class of drugs that stimulate the pancreas to release insulin, e.g., glipizide, glyburide), GLP-1 agonists (glucagon-like peptide-1 receptor agonists, e.g., semaglutide)): GH antagonizes insulin action; insulin and sulfonylurea doses may need upward adjustment. Monitor glucose.

• Glucocorticoids (prednisone, dexamethasone): Suppress the GH axis and blunt response; concurrent chronic steroid use reduces efficacy. Monitor.

• Thyroid hormone (levothyroxine): Sustained GH elevation can increase T4-to-T3 conversion and unmask subclinical hypothyroidism; thyroid status may need reassessment after starting.

• Estrogens (oral, transdermal) and SERMs (selective estrogen receptor modulators, e.g., tamoxifen, raloxifene): Oral estrogen blunts hepatic IGF-1 production; response may be smaller in women on oral estrogen than transdermal. Caution, adjust expectations.

• Over-the-counter medications: Chronic NSAIDs (non-steroidal anti-inflammatory drugs, e.g., ibuprofen, naproxen) do not pharmacokinetically interact with CJC-1295 but can compound fluid-retention and blood-pressure effects of GH elevation — monitor during concurrent use. OTC antihistamines, H2 blockers (famotidine), and proton-pump inhibitors (omeprazole) have no known direct interaction. Melatonin may potentiate GH pulses slightly via sleep-architecture effects; generally not clinically significant.

• Supplements with additive GH/IGF-1 effects: Arginine, ornithine, glycine at high doses, GABA (gamma-aminobutyric acid, a calming neurotransmitter sometimes taken as a supplement), and glutamine can modestly stimulate endogenous GH; additive effect is usually minor. Monitor.

• Supplements affecting insulin sensitivity: Berberine, chromium, alpha-lipoic acid may partially offset GH-induced insulin resistance; not a reason to use CJC-1295 but relevant if co-taken.

• Populations who should avoid:

  • Active malignancy — absolute contraindication due to IGF-1 proliferative signaling
  • History of hormone-sensitive cancer within 5 years — absolute contraindication
  • Pregnancy or lactation — absolute contraindication, no safety data
  • Age under 21 years with closed growth plates unverified — absolute contraindication
  • Active retinopathy (diabetic or other proliferative) — absolute contraindication, IGF-1 promotes retinal neovascularization
  • Uncontrolled diabetes (HbA1c >8%) — absolute contraindication
  • Severe heart failure (NYHA (New York Heart Association functional classification for heart failure severity) Class III–IV) — absolute contraindication
  • Known pituitary adenoma — caution; endocrinology consultation required
  • Competitive athletes subject to WADA or sport anti-doping testing — prohibited substance

Risk Mitigation Strategies

• Pharmaceutical-grade sourcing only: Obtain CJC-1295 only through a licensed compounding pharmacy operating under state and federal oversight, with a valid prescription from a physician familiar with the agent. This mitigates the dominant real-world risk — contamination, misidentification, and variable potency from “research use only” supply.

• Baseline screening before initiation: Verify no active or recent hormone-sensitive malignancy, obtain fasting glucose/HbA1c/IGF-1/IGFBP-3 (insulin-like growth factor binding protein 3, the main IGF-1 carrier), and age-appropriate cancer screening (e.g., PSA (prostate-specific antigen) in men >45, mammography/colonoscopy on current schedule). Prevents initiation in contraindicated individuals.

• Start low, titrate cautiously: Typical practice-based starting dose is 100 µg twice weekly (no-DAC form) or 1,000–2,000 µg weekly (DAC form), with titration based on IGF-1 response after 4–6 weeks. Lower starting doses reduce fluid retention, glucose elevation, and carpal tunnel symptoms.

• Cap IGF-1 within age-adjusted reference range: Target IGF-1 at the 50–75th percentile for age, not supraphysiological. Dose-adjust downward if IGF-1 exceeds the age-adjusted upper reference limit. Mitigates the principal theoretical long-term risk (cancer signaling, cardiac remodeling).

• Cycle off periodically: Typical cycling practice is 8–12 weeks on, 4 weeks off, or continuous use with a scheduled break every 6 months. Cycling addresses concerns about receptor desensitization, sustained insulin resistance, and cumulative IGF-1 exposure.

• Monitor metabolic markers quarterly: Fasting glucose, HbA1c, and fasting insulin every 3 months during active use. Allows early detection of GH-induced insulin resistance before it becomes symptomatic.

• Dose in the evening: Dosing 2–3 hours before bed aligns the induced GH pulse with physiological timing and may reduce daytime fluid retention and cognitive dullness. Mitigates side-effect burden.

• Rotate injection sites and use sterile technique: Alternate abdominal quadrants and upper-thigh sites; use single-use insulin syringes; reconstitute with bacteriostatic water and refrigerate. Mitigates injection-site reactions and infection risk.

• Stop and reassess if symptoms emerge: Persistent edema >2 weeks, new carpal tunnel symptoms, rising fasting glucose, or any new swelling/mass warrants immediate pause and physician evaluation.

Therapeutic Protocol

A standard protocol does not exist in the regulatory sense — no FDA-approved label specifies dosing. The practice-based protocols below reflect what is commonly used in longevity and anti-aging clinics, drawing from physicians including Craig Koniver, William Seeds (author of the Seeds Protocol), and practitioners in the International Peptide Society. Conflict of interest note: these physicians, their affiliated clinics, and the International Peptide Society derive direct revenue from prescribing peptide therapies; their dosing recommendations cannot be treated as disinterested clinical guidance. The same applies to the compounding pharmacies named later in this review. Where competing approaches exist, they are presented without framing one as default.

Approach 1: DAC form, once or twice weekly. Typical dosing is 1,000–2,000 µg subcutaneously once or twice weekly. Popularized by ConjuChem’s original trial protocols and carried forward by longevity clinics seeking convenience. The DAC form produces continuous elevated trough GH, which is mechanistically non-physiological but dosing-convenient.

Approach 2: No-DAC form (Modified GRF 1-29), multiple times weekly. Typical dosing is 100 µg subcutaneously 2–3 times daily, or 100–300 µg at bedtime. Popularized by bodybuilding and anti-aging practitioners who argue that short-acting pulses more closely mimic physiological GHRH secretion. Often combined with 100–300 µg ipamorelin at the same injection.

Approach 3: Combined CJC-1295/ipamorelin stack. The most common longevity-clinic approach combines CJC-1295 (usually no-DAC or low-dose DAC) with ipamorelin, a selective ghrelin-receptor agonist. Rationale: dual-pathway GH stimulation (GHRH receptor + ghrelin receptor) produces larger, cleaner GH pulses than either alone. No head-to-head trials establish superiority.

Best time of day: Evening dosing (2–3 hours before sleep) aligns induced GH pulses with endogenous slow-wave sleep–linked GH release. Some protocols use split morning/evening dosing with no-DAC forms.

Half-life: DAC form ~5.8–8.1 days; no-DAC form ~30 minutes. Elimination of any clinical activity takes ~5 half-lives.

Single vs. split dosing: DAC form is inherently once/twice-weekly due to its half-life. No-DAC form is typically split into multiple daily doses to approximate pulsatile secretion.

Genetic polymorphisms: No well-established pharmacogenetic variants specifically alter CJC-1295 response. GHR (growth hormone receptor) exon-3 deletion polymorphism modifies downstream GH signaling and may affect response magnitude; IGF-1 promoter polymorphisms affect baseline IGF-1 and may influence titration targets.

Sex-based differences: Women typically show smaller IGF-1 response at equivalent doses, particularly on oral estrogen. Most published trial data are in men; dose extrapolation introduces uncertainty.

Age-related considerations: Older adults (55+) often have lower baseline IGF-1 and show larger relative response; they also have reduced reserve for managing side effects. Conservative starting doses and slower titration are standard.

Baseline biomarker considerations: Baseline IGF-1 in the lower tertile for age favors a meaningful response; baseline IGF-1 near the upper reference limit argues against initiation or for minimal dosing.

Pre-existing conditions: Diabetes, metabolic syndrome, or active proliferative retinopathy each argue against use or for reduced dosing. Uncontrolled hypertension and sleep apnea are relative contraindications pending stabilization.

Discontinuation & Cycling

• Lifelong vs. short-term: CJC-1295 is generally not intended as a lifelong therapy in the longevity context — most clinical protocols build in scheduled breaks.
• Withdrawal effects: Withdrawal effects are minor: induced GH/IGF-1 elevation returns to baseline over approximately 2–4 weeks (DAC form has the longer taper due to its half-life), with no physical-dependence withdrawal syndrome. Some users report a subjective “crash” in energy or sleep quality during this reversion, which is consistent with return to baseline rather than rebound suppression.
• Tapering: No formal tapering protocol is required — the long half-life of the DAC form produces an inherent pharmacokinetic taper.
• Cycling: Cycling is commonly recommended in practice for several overlapping reasons: theoretical concern about receptor desensitization, mitigation of cumulative IGF-1 exposure, periodic reassessment of need, and cost. Typical cycles are 8–12 weeks on followed by 4 weeks off, or continuous use with a mandatory 4-week break every 6 months. Direct trial evidence that cycling changes efficacy or safety outcomes is absent.

Sourcing and Quality

• Compounded from a licensed 503A pharmacy with valid prescription: The only sourcing route that provides pharmaceutical-grade identity, purity, and sterility assurance in the US. Requires a physician prescription and varies by state law; regulatory status has shifted multiple times and availability may depend on current FDA category placement.

• Third-party certificates of analysis: Regardless of source, require a recent (within 6 months) third-party CoA (certificate of analysis) documenting peptide identity by mass spectrometry, purity ≥98% by HPLC (high-performance liquid chromatography, a lab technique that measures a compound’s purity), endotoxin <0.5 EU/mg, and absence of bacterial contamination. Certificates should be from an independent lab, not the seller’s internal testing.

• Avoid “research use only” online suppliers: These are unregulated, frequently mislabeled, and have been the source of identified contamination and incorrect-compound events. “Research use only” labeling is a legal disclaimer, not a quality signal.

• Storage and reconstitution: Lyophilized peptide should be shipped cold and stored refrigerated (2–8°C). After reconstitution with bacteriostatic water, refrigerate and use within 14–30 days. Improper storage degrades the peptide and can cause injection-site reactions from degradation products.

• Reputable compounding pharmacies: Several US 503A compounding pharmacies (e.g., Empower Pharmacy, Tailor Made Compounding, Olympia Pharmaceutical) have historically prepared CJC-1295 for prescribers — availability depends on current regulatory status and varies over time. Verify each pharmacy’s current capability before assuming availability.

Practical Considerations

• Time to effect: Biochemical changes (IGF-1 elevation) are measurable within 1 week; subjective effects on sleep and recovery often reported within 2–4 weeks; body-composition changes typically require 8–12 weeks of consistent use.

• Common pitfalls:
  • Using non-pharmaceutical-grade “research” product and attributing poor response or side effects to the compound rather than the supply
  • Stacking multiple GH-axis agents (CJC-1295 + ipamorelin + MK-677 + tesamorelin) without understanding additive risk
  • Failing to measure baseline and on-treatment IGF-1 and thereby missing supraphysiological elevation
  • Dosing in the morning and attributing daytime fatigue or puffiness to the drug rather than to mistimed administration
  • Ignoring fasting-glucose drift that emerges over 4–8 weeks
  • Continuing indefinitely without scheduled reassessment or breaks

• Regulatory status: Not FDA-approved for any indication. Regulatory status for compounding pharmacies has shifted between 2023 and 2026 — from unrestricted, to Category 2 (restricted), to removed-from-Category-2 (permitted but not approved), and is subject to further PCAC review. Prohibited by WADA for competitive athletes.

• Cost and accessibility: Typical 503A compounding pharmacy pricing runs $150–$400 per month for CJC-1295/ipamorelin combinations, plus clinic consultation fees, putting a year of use at roughly $2,500–$7,500 all-in. Access requires a prescribing physician and is not covered by insurance. Gray-market supply is cheaper but carries the sourcing risks described above.

Interaction with Foundational Habits

• Sleep: Potentiating interaction, bidirectional. CJC-1295 dosed in the evening tends to deepen slow-wave sleep and is the most consistent user-reported benefit. Conversely, chronic sleep restriction blunts endogenous GH pulses and the response to any secretagogue. Practical: dose 2–3 hours before bedtime; prioritize sleep hygiene before assessing efficacy.

• Nutrition: Modulating interaction. Sustained carbohydrate excess and hyperinsulinemia antagonize the IGF-1–mediated anabolic response and exacerbate GH-induced insulin resistance. Adequate protein intake (1.6–2.2 g/kg lean body mass) is required to translate biochemical anabolic signaling into tissue-level benefit. Avoid eating for ~2 hours before and 30 minutes after evening dosing — acute hyperinsulinemia blunts the induced GH pulse.

• Exercise: Potentiating interaction with resistance training; neutral-to-blunting on aerobic endurance. Resistance training and IGF-1 signaling are synergistic for lean-mass outcomes. Without a resistance-training stimulus, CJC-1295 produces biochemical change with limited functional translation. Timing: pre-workout or post-workout dosing does not reliably outperform bedtime dosing in available data.

• Stress management: Blunting interaction from chronic stress. Chronically elevated cortisol opposes GH/IGF-1 signaling at tissue level and reduces the anabolic efficiency of any induced GH pulse. Chronic psychological stress, untreated sleep apnea, and overtraining all substantially reduce the real-world benefit of CJC-1295. Stress management is a prerequisite, not an adjunct.

Monitoring Protocol & Defining Success

Baseline laboratory assessment establishes a safe starting point and defines response targets; ongoing monitoring tracks efficacy, detects supraphysiological drift, and screens for adverse effects.

Ongoing monitoring cadence: at 4 weeks (early IGF-1 response and glucose), at 12 weeks (body composition and full panel), and every 6 months thereafter for continuous use.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
IGF-1	50th–75th percentile for age and sex	Primary response marker; also the principal safety endpoint	Conventional reference range is age-stratified and very wide; functional targeting avoids supraphysiological drift. Measure at baseline, 4 weeks, 12 weeks, then every 6 months. Non-fasting acceptable; avoid measuring within 24 hours of a DAC dose.
IGFBP-3	Age-appropriate reference range	Paired with IGF-1 to assess bioavailable IGF-1 and axis integrity	Low IGFBP-3 with high IGF-1 suggests higher free IGF-1 exposure. Non-fasting acceptable.
Fasting glucose	75–90 mg/dL	Detects GH-induced insulin resistance	Conventional reference range extends to 99 mg/dL; functional range is tighter to catch early drift. Measure fasting, morning, before dosing.
HbA1c	<5.4%	Integrates glycemic control over ~3 months	Conventional range allows up to 5.6% (normal) or 5.7–6.4% (prediabetes); functional practitioners target <5.4%. Measure every 3 months during active use.
Fasting insulin	<7 µIU/mL	Sensitive early marker of insulin resistance before glucose rises	Conventional labs often flag only >25 µIU/mL; functional targeting catches subclinical drift. Fasting, morning draw.
HOMA-IR	<1.5	Calculated index of insulin resistance	HOMA-IR = Homeostasis Model Assessment of Insulin Resistance. Computed from fasting glucose × fasting insulin ÷ 405. Sensitive to early metabolic drift on GH-axis therapy.
Fasting lipid panel	Total:HDL <3.5; triglycerides <100 mg/dL	GH affects lipolysis and lipoprotein metabolism	Fasting 12 hours; baseline and every 6 months.
CBC	Within reference range	Screens for hematocrit elevation	CBC = complete blood count. GH can modestly elevate hematocrit; monitor with androgen co-therapy.
Comprehensive metabolic panel	Within reference range	Liver/kidney function; electrolytes	Baseline and every 6 months; fluid retention may affect creatinine.
PSA (men ≥45)	Below age-adjusted cutoff	Screens for prostate pathology given IGF-1 signaling	Baseline and annually during use; halt and investigate any meaningful rise.
Blood pressure	<120/80 mmHg	Fluid retention can elevate BP	Home measurement recommended; weekly during first 4 weeks, then monthly.
Body composition (DEXA)	Stable or improving lean mass / fat mass	Validates body-composition benefit claim	DEXA = dual-energy X-ray absorptiometry, a body-composition scan. Baseline and at 12 weeks. Optional but informative.

Qualitative markers:

• Sleep quality and slow-wave sleep duration (subjective or wearable-tracked)
• Morning facial puffiness or peripheral edema (presence/absence, severity)
• Hand/wrist tingling or numbness suggestive of nerve compression
• Joint aches or stiffness
• Recovery from training sessions (subjective)
• Energy and cognitive clarity (subjective)
• Skin texture, thickness, and hair/nail quality (subjective, over months)
• Injection-site appearance (redness, induration, persistent nodules)

Emerging Research

• Category 2 peptide reclassification and PCAC review: The FDA’s 2024 removal of CJC-1295 from Category 2 of the interim compounding policy — and the scheduled subsequent PCAC review of multiple peptides — could shift the regulatory landscape meaningfully over 2026–2027. The outcome could either restrict CJC-1295 again (if safety signals accumulate) or place it on a positive 503A bulks list (if data support it). Relevant because it is the single largest near-term driver of legitimate access.

• Longer-duration GH secretagogue safety studies: Areas of future research that could change current understanding include multi-year controlled trials of any GH secretagogue (including the FDA-approved tesamorelin) measuring cardiovascular, neoplastic, and metabolic endpoints in originally healthy adults. No such trials are currently enrolling for CJC-1295 specifically.

• Ongoing clinical trials: A search of clinicaltrials.gov identifies one historical Phase II trial in HIV-associated visceral obesity, NCT00267527 (120 participants, terminated), with no active or recruiting trials of CJC-1295 as of review date. The absence of active trials is itself notable and reflects the compound’s drift from pharmaceutical development into off-label practice.

• GH/IGF-1 axis and longevity — conflicting evidence directions: Emerging research cuts both ways. Studies of Laron-syndrome cohorts (severe GHR deficiency) and of the GH/IGF-1 pathway in centenarians suggest reduced, not elevated, GH/IGF-1 signaling is associated with longer lifespan. Conversely, human trials in GH-deficient adults show improvements in body composition and quality of life without excess mortality over trial durations. The net longevity effect of supraphysiological IGF-1 exposure from a GHRH secretagogue in non-deficient adults is a live research question.

• Alternative GHRH-axis agents: Development interest in tesamorelin (FDA-approved for HIV-lipodystrophy) for metabolic and cognitive indications in non-HIV populations could indirectly inform the GHRH-analog safety profile generally. Mechanistically relevant publications include Baker et al., 2012 on GHRH effects on cognition in older adults with mild cognitive impairment.

• Detection science advances: Parallel research on CJC-1295 detection methods — driven by anti-doping surveillance — continues. Work by Memdouh et al., 2021 on synthetic GHRH analog detection represents the current state of the art and has practical implications for athletes and for any future regulated-use framework.

Conclusion

CJC-1295 is a long-acting synthetic peptide that reliably raises growth hormone and its downstream messenger for days to weeks from a single subcutaneous injection — a pharmacological effect documented in small short-duration human trials. Beyond this biochemical action, the evidence base for real-world health and longevity benefits is thin. Reported benefits on body composition, sleep, recovery, and skin quality are mechanistically plausible and consistent with practice-based observation, but rest on a trial base that is small, short, and largely predates rigorous longevity-outcome study design. Side effects include fluid retention, carpal tunnel symptoms, impaired glucose tolerance, and injection-site reactions, most of which are manageable with dose titration. The larger uncertainties — whether multi-year supraphysiological growth-hormone-axis exposure meaningfully alters cancer risk, cardiac structure, or long-term metabolic function in originally healthy adults — are genuinely unresolved. Real-world risk is further dominated by supply-side issues: most non-clinic product is unregulated and variable in purity. Regulatory status has shifted repeatedly and the compound remains unapproved for any indication. Much of the practice-level guidance comes from longevity-clinic physicians, membership organizations, and compounding pharmacies that derive direct revenue from prescribing or dispensing the peptide, and the existing human literature is small enough that this financial interest materially shapes the available guidance. The central tension in this literature is between a well-characterized short-term pharmacology and a still-small, short-duration human evidence base for an unapproved hormone agent.

Top - Benefits - Risks - Protocol